TENDU was designed to include long synthetic peptides harboring prostate cancer-derived epitopes (CD4 and CD8) from PAP and PSMA, as well as the previously identified prostate cancer antigen NY-ESO1.19 Here, CD4 is linked to prostate carcinoma.